[{"id":"3ffb83b9-b7f6-4a1b-b219-82bb668c8ae7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03847519","created_at":"2021-01-18T18:59:33.778Z","updated_at":"2024-07-02T16:34:59.300Z","phase":"Phase 1/2","brief_title":"Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03847519","lead_sponsor":"Advaxis, Inc.","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK translocation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • OST-503"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 02/22/2022","primary_completion_date":" 02/22/2022","study_txt":" Completion: 02/22/2022","study_completion_date":" 02/22/2022","last_update_posted":"2024-06-04"}]